Loading
Life sciences · Journal article
Healthcare · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: This study was conducted to prospectively evaluate quality of life (QoL), patient-reported outcomes, and geriatric domains during the first 3 months of first-line systemic therapy in older patients with de novo metastatic gastrointestinal cancers. Methods: This prospective longitudinal study included 90 patients aged ≥65 years receiving first-line chemotherapy-based systemic therapy. Assessments were performed at baseline, Month 1, and Month 3 using validated QoL, sleep, anxiety, cognitive, and nutritional instruments. The primary endpoint was change in EORTC QLQ-C30 Global Health Status/QoL from baseline to Month 3. Treatment tolerability, initial radiologic response, and exploratory survival outcomes were also assessed. Results: Mean Global Health Status/QoL increased from 68.1 at baseline to 71.0 at Month 3; the model-estimated mean change was +3.0 points (95% CI, −0.3 to 6.2; p = 0.071). Fatigue and appetite loss improved significantly, and normal nutritional status increased from 31.1% to 62.2% (p < 0.001). Clinically meaningful QoL improvement and deterioration occurred in 38.9% and 18.9%, respectively. Treatment intolerance occurred in 46.7%. Disease control was associated with more favorable QoL change than progressive disease (difference, 17.8 points; 95% CI, 6.0–29.7; FDR-adjusted p = 0.008). Baseline nutritional impairment (adjusted HR, 3.58) and poor sleep quality (adjusted HR, 3.30) were associated with shorter progression-free survival. Conclusions: Mean global QoL did not change significantly during the first 3 months, while several symptom and nutritional domains improved. More favorable QoL trajectories were observed with disease control, and baseline nutritional impairment and poor sleep quality were associated with shorter progression-free survival.